tradingkey.logo

Dogwood Therapeutics Inc

DWTX
View Detailed Chart
3.170USD
0.0000.00%
Close 02/06, 16:00ETQuotes delayed by 15 min
7.27MMarket Cap
0.03P/E TTM

Dogwood Therapeutics Inc

3.170
0.0000.00%
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

+13.62%

1 Month

-20.15%

6 Months

-33.35%

Year to Date

-23.80%

1 Year

-73.16%

View Detailed Chart

Key Insights

Dogwood Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 190 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dogwood Therapeutics Inc's Score

Industry at a Glance

Industry Ranking
190 / 392
Overall Ranking
363 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Dogwood Therapeutics Inc Highlights

StrengthsRisks
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Overvalued
The company’s latest PE is 0.03, at a high 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 29.95K shares of this stock.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
19.000
Target Price
+499.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dogwood Therapeutics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Dogwood Therapeutics Inc Info

Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Ticker SymbolDWTX
CompanyDogwood Therapeutics Inc
CEODuncan (Gregory Scott)
Websitehttps://dwtx.com/
KeyAI